Cabaletta Bio (CABA) Cash from Financing Activities (2018 - 2025)
Cabaletta Bio's quarterly Cash from Financing Activities came in at $8.3 million in Q4 2025, up 90.58% year-on-year from $4.4 million in Q4 2024, and up 1133.75% quarter-over-quarter from -$806000.0 in Q3 2025.
Cabaletta Bio has reported Cash from Financing Activities for 8 years, with the latest figure at $8.3 million in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities rose 90.58% year-over-year to $8.3 million; the trailing twelve-month figure through Dec 2025 stood at $100.3 million (up 759.36% YoY), and the FY2025 full-year result was $100.3 million, up 759.36% from the prior year.
- Cash from Financing Activities for Q4 2025 stood at $8.3 million, up from -$806000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $94.3 million in Q2 2023, with the low at -$806000.0 in Q3 2025.
- Average Cash from Financing Activities over 5 years is $20.1 million, with a median of $4.4 million recorded in 2024.
- Year-over-year, Cash from Financing Activities jumped 235545.0% in 2023 and slumped 1235.21% in 2025.
- Tracing CABA's Cash from Financing Activities over 5 years: stood at $13.6 million in 2021, then jumped by 141.35% to $32.9 million in 2022, then surged by 182.9% to $93.0 million in 2023, then plunged by 95.3% to $4.4 million in 2024, then jumped by 90.58% to $8.3 million in 2025.
- The last three Cash from Financing Activities figures came in at $8.3 million (Q4 2025), -$806000.0 (Q3 2025), and $93.4 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -802.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Cabaletta Bio | 194.84 Mn | 61.24 Mn | - | 8.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.33 Mn |
| Dec 31, 2025 | 8.33 Mn |
| Sep 30, 2025 | -806,000.00 |
| Sep 30, 2025 | -806,000.00 |
| Jun 30, 2025 | 93.37 Mn |
| Jun 30, 2025 | 93.37 Mn |
| Mar 31, 2025 | -552,000.00 |
| Mar 31, 2025 | -552,000.00 |
| Dec 31, 2024 | 4.37 Mn |
| Dec 31, 2024 | 4.37 Mn |
| Sep 30, 2024 | 71,000.00 |
| Sep 30, 2024 | 71,000.00 |
| Jun 30, 2024 | 379,000.00 |
| Jun 30, 2024 | 379,000.00 |
| Mar 31, 2024 | 6.86 Mn |
| Mar 31, 2024 | 6.86 Mn |
| Dec 31, 2023 | 93.05 Mn |
| Dec 31, 2023 | 93.05 Mn |
| Sep 30, 2023 | 98,000.00 |
| Sep 30, 2023 | 98,000.00 |
| Jun 30, 2023 | 94.26 Mn |
| Jun 30, 2023 | 94.26 Mn |
| Mar 31, 2023 | 226,000.00 |
| Mar 31, 2023 | 226,000.00 |
| Dec 31, 2022 | 32.89 Mn |
| Dec 31, 2022 | 32.89 Mn |
| Jun 30, 2022 | 40,000.00 |
| Jun 30, 2022 | 40,000.00 |
| Mar 31, 2022 | 51,000.00 |
| Mar 31, 2022 | 51,000.00 |
| Dec 31, 2021 | 13.63 Mn |
| Dec 31, 2021 | 13.63 Mn |
| Sep 30, 2021 | 25.34 Mn |
| Sep 30, 2021 | 25.34 Mn |
| Jun 30, 2021 | 7.77 Mn |
| Jun 30, 2021 | 7.77 Mn |
| Mar 31, 2021 | 2.17 Mn |
| Mar 31, 2021 | 2.17 Mn |
| Dec 31, 2020 | 32,000.00 |
| Dec 31, 2020 | 32,000.00 |
| Sep 30, 2020 | 135,000.00 |
| Sep 30, 2020 | 135,000.00 |
| Jun 30, 2020 | -147,000.00 |
| Jun 30, 2020 | -147,000.00 |
| Mar 31, 2020 | -44,000.00 |
| Mar 31, 2020 | -44,000.00 |
| Dec 31, 2019 | 73.32 Mn |
| Dec 31, 2019 | 73.32 Mn |
| Sep 30, 2019 | -2.10 Mn |
| Sep 30, 2019 | -2.10 Mn |
| Jun 30, 2019 | -956,000.00 |
| Jun 30, 2019 | -956,000.00 |
| Mar 31, 2019 | 49.66 Mn |
| Mar 31, 2019 | 49.66 Mn |
| Dec 31, 2018 | 25.14 Mn |
| Dec 31, 2018 | 25.14 Mn |